FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients. However, the FDA pointed to the drug’s benefits, as well. “Alzheimer’s disease immeasurably incapacitatesContinue Reading

FRIDAY, Jan. 6, 2023 (HealthDay News) — Patients with an incurable, genetic liver disease have new hope after an animal study showed that a single drug could reverse its effects. Alagille syndrome is caused by a mutation that prevents the formation and regeneration of bile ducts in the liver. AboutContinue Reading